New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
09:02 EDTSGEN, RHHBYSeattle Genetics to receive milestone payments as Genentech advances two ADCs
Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.
News For SGEN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
10:00 EDTSGENOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:49 EDTSGENSeattle Genetics upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 30, 2014
16:30 EDTSGENSeattle Genetics sees FY14 revenue from ADCETRIS $172M-$177M
Seattle Genetics anticipates that 2014 revenues from ADCETRIS net product sales in the U.S. and Canada will be higher than previously anticipated, and are now expected to be in the range of $172M-$177M. The company also anticipates that 2014 collaboration revenues will be higher than previously anticipated, and are now expected to be in the range of $64M-$68M.
16:30 EDTSGENSeattle Genetics reports Q3 EPS (13c), consensus (24c)
Subscribe for More Information
October 29, 2014
13:09 EDTSGENSeattle Genetics management to meet with Jefferies
Subscribe for More Information
October 28, 2014
11:14 EDTRHHBYRoche unit announces collaboration pact with ImmunoGen
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with ImmunoGen (IMGN) to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha, or FRa, that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate.
October 27, 2014
20:54 EDTRHHBYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:52 EDTSGENSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
07:20 EDTRHHBYAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
October 21, 2014
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use